A Phase II Trial of HL-085+Vemurafenib to Treat Advanced Melanoma Patients With BRAF V600E/K Mutation
Status:
Recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to Evaluate the Efficacy and Safety of the combination of
HL-085 and Vemurafenib in Advanced Melanoma Patients with BRAF V600E/K Mutation. This study
includes IIa and IIb phase. Phase IIa will determine the dose regiment for Phase IIb. Phase
IIb part will evaluate the efficacy and safety with this combination regiment.